Eisai initiates new trial for advanced kidney cancer

Eisai has announced the initiation of a new trial designed to evaluate the efficacy of a combined therapy for patients suffering from advanced kidney cancer.

The study is a randomised phase III trial that assesses the efficacy and safety of lenvatinib in combination with anti-PD-1 immunotherapy pembrolizumab (Keytruda) and lenvatinib in combination with everolimus versus sunitinib. It’s designed to analyse the progression-free survival (PFS) of patient treated with the aforementioned combinations.

The study will also potentially assess objective response rate and overall survival and safety.

Kidney cancer is among the ten most frequently occurring cancers in Western countries signaling the need for new studies into the disease. About 270,000 cases of kidney cancer are diagnosed globally each year and 116,000 people die from the disease. Approximately 90% of all kidney cancers are renal cell carcinomas (RCC).